文献速递血管炎

ANCA相关血管炎中肺孢子菌肺炎风险的时间依赖预测模型开发

Development of a time-dependent prediction model for the risk of Pneumocystis jirovecii pneumonia in ANCA-associated vasculitis.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究基于全国理赔数据库的回顾性队列,纳入2015至2024年新诊断的2751例ANCA相关血管炎患者,开发时间依赖预测模型以评估肺孢子菌肺炎风险。最终模型纳入年龄、每月最大糖皮质激素剂量、利妥昔单抗、环磷酰胺和PJP预防用药,内部-外部交叉验证显示时间依赖C指数在2个月为0.70(95%CI 0.60-0.79)、12个月为0.66(95%CI 0.61-0.71),校准可接受。模型可能支持更适当的个体化预防决策。

要点

  • 在2751例ANCA相关血管炎患者中,170例(6.2%)发生肺孢子菌肺炎。
  • 时间依赖预测模型纳入年龄、每月最大激素剂量、利妥昔单抗、环磷酰胺和PJP预防。
  • 以每月风险阈值1.0%计算,每1000例患者中948例会被推荐预防。

核心结论

  • 开发了时间依赖模型预测ANCA相关血管炎患者肺孢子菌肺炎风险,可能支持更适当的个体化预防决策。

研究设计与样本

  • 回顾性队列研究,使用全国理赔数据库,纳入2015至2024年新诊断的ANCA相关血管炎患者2751例。

主要发现

  • 170例(6.2%)患者发生肺孢子菌肺炎。
  • 内部-外部交叉验证中,时间依赖C指数在2个月为0.70(95%CI 0.60-0.79),12个月为0.66(95%CI 0.61-0.71),校准总体可接受。

关键数值与推荐

  • 最终模型纳入年龄、每月最大糖皮质激素剂量、利妥昔单抗使用、环磷酰胺使用和PJP预防。
  • 以每月风险阈值1.0%计算,每1000例患者(含61例PJP)中948例会被推荐预防,其中643例未接受预防,34例PJP可能可预防,336例可在随访中停止预防。

临床怎么用

  • 该模型可辅助临床医生根据患者动态风险个体化决定是否启动或停止肺孢子菌肺炎预防。

局限性

  • 本研究为回顾性队列研究,基于理赔数据库,可能存在未测量混杂和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In patients with ANCA-associated vasculitis (AAV), Pneumocystis jirovecii pneumonia (PJP) is a potentially fatal complication. As treatment intensity typically changes over time, PJP risk also changes, making fixed prophylaxis strategies suboptimal. We aimed to develop a time-dependent prediction model to guide individualized decisions on PJP prophylaxis. METHODS: We conducted a retrospective cohort study using a nationwide claims database. Patients newly diagnosed with AAV between 2015 and 2024 were included. Candidate predictors included demographics, comorbidities and monthly updated medication use. A flexible parametric survival model was developed to predict the risk of PJP. Discrimination, calibration and clinical utility were evaluated by internal-external cross-validation (IECV) to investigate model's generalizability. RESULTS: Among 15 649 036 individuals in the database, 2751 patients with AAV were included. Of them, 170 (6.2%) developed PJP. The final model included age, monthly maximum glucocorticoid dose, use of rituximab, CYC and PJP prophylaxis. In the IECV, the time-dependent C-index was 0.70 (95% CI 0.60-0.79) at 2 months and 0.66 (95% CI 0.61-0.71) at 12 months; calibration was generally acceptable. In the clinical utility analysis, per 1000 patients with AAV including 61 PJP cases, 948 would be recommended prophylaxis with a monthly risk threshold of 1.0%. Of them, 643 had not received it, with 34 potentially preventable PJP cases, and 336 could have discontinued prophylaxis during follow-up. CONCLUSION: We developed a time-dependent model to predict the risk of PJP in patients with AAV. The model may support more appropriate, individualized prophylaxis decisions.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Takada T, Hoogland J, Anan K, et al. Development of a time-dependent prediction model for the risk of Pneumocystis jirovecii pneumonia in ANCA-associated vasculitis. Rheumatology (Oxford). 2026. PMID: 41936077. doi:10.1093/rheumatology/keag168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。